Abiopharma

🔍 Thurmond Mark C. (Director)

Company: Tenable Holdings, Inc. (TENB)

Report Date: 2026-08-24

Detailed Transactions and Holdings:

• Acquired 1,162 shares of Common Stock (Direct)
  Date: 2026-08-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 183,350.00 | transaction_form_type: 4
• Sold 562 shares of Common Stock at $33.94 per share (Direct)
  Date: 2026-08-24 | Code: F | equity_swap_involved: 0 | shares_owned_after: 182,788.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,267 shares of Common Stock (Direct)
  Date: 2026-08-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 185,055.00 | transaction_form_type: 4
• Sold 1,097 shares of Common Stock at $33.94 per share (Direct)
  Date: 2026-08-24 | Code: F | equity_swap_involved: 0 | shares_owned_after: 183,958.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 6,095 shares of Common Stock (Direct)
  Date: 2026-08-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 190,053.00 | transaction_form_type: 4
• Sold 2,947 shares of Common Stock at $33.94 per share (Direct)
  Date: 2026-08-24 | Code: F | equity_swap_involved: 0 | shares_owned_after: 187,106.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 3,713 shares of Common Stock (Direct)
  Date: 2026-08-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 190,819.00 | transaction_form_type: 4
• Sold 1,796 shares of Common Stock at $33.94 per share (Direct)
  Date: 2026-08-24 | Code: F | equity_swap_involved: 0 | shares_owned_after: 189,023.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 7,764 shares of Common Stock (Direct)
  Date: 2026-08-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 196,787.00 | transaction_form_type: 4
• Sold 3,754 shares of Common Stock at $33.94 per share (Direct)
  Date: 2026-08-24 | Code: F | equity_swap_involved: 0 | shares_owned_after: 193,033.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 4,368 shares of Common Stock (Direct)
  Date: 2026-08-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 197,401.00 | transaction_form_type: 4
• Sold 2,112 shares of Common Stock at $33.94 per share (Direct)
  Date: 2026-08-24 | Code: F | equity_swap_involved: 0 | shares_owned_after: 195,289.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,162 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,330.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3
• Sold 2,267 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 13,606.00 | transaction_form_type: 4 | Footnotes: F2, F4, F4
• Sold 6,095 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 60,957.00 | transaction_form_type: 4 | Footnotes: F2, F5, F5
• Sold 3,713 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 7,426.00 | transaction_form_type: 4 | Footnotes: F2, F6, F6
• Sold 7,764 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 77,644.00 | transaction_form_type: 4 | Footnotes: F2, F7, F7
• Sold 4,368 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 26,208.00 | transaction_form_type: 4 | Footnotes: F2, F8, F8

Footnotes:

• F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the Restricted Stock Units ("RSUs") and does not represent a sale.
• F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
• F3: On February 21, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the Performance Restricted Stock Units (PRSUs) granted on February 22, 2023 and determined a 93.9% payout for the measurement period based on the Issuer's fiscal year 2023 criteria. 25% of the shares underlying the PRSUs vested on February 22, 2024, with the remainder vesting in equal quarterly installments over 3 years, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date, and subject to accelerated vesting in specified circumstances.
• F4: On February 13, 2025, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the Performance Restricted Stock Units (PRSUs) granted on February 22, 2024 and determined a 96.4% payout for the measurement period based on the Issuer's fiscal year 2024 criteria. 25% of the shares underlying the PRSUs vested on February 22, 2025, with the remainder vesting in equal quarterly installments over 3 years, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date, and subject to accelerated vesting in specified circumstances.
• F5: On February 25, 2026, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the Performance Restricted Stock Units (PRSUs) granted on February 21, 2025 and determined a 97.2% payout for the measurement period based on the Issuer's fiscal year 2025 criteria. 25% of the shares underlying the PRSUs vested on February 25, 2026, with the remainder vesting in equal quarterly installments over 3 years, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date, and subject to accelerated vesting in specified circumstances.
• F6: 25% of the shares underlying the RSUs vested on February 22, 2024, with the remainder vesting in equal quarterly installments over 3 years, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date, and subject to accelerated vesting in specified circumstances.
• F7: 25% of the shares underlying the RSUs vested on August 22, 2025, 25% on February 22, 2026, with the remainder vesting in equal quarterly installments over 3 years, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date, and subject to accelerated vesting in specified circumstances.
• F8: 25% of the shares underlying the RSUs vested on February 22, 2025, with the remainder vesting in equal quarterly installments over 3 years, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date, and subject to accelerated vesting in specified circumstances.